Which biomarkers are useful to guide management when pneumonia or heart failure is suspected?

• A. CRP and ESR
• B. D-dimer and fibrinogen
• C. Troponin I and CK-MD
• D. BNP and procalcitonin levels

Answer: (D)

Distinguishing infection from heart failure and guiding treatment relies on biomarkers that reflect infection and cardiac stress. Procalcitonin rises with bacterial infection and helps determine whether antibiotics are needed and how long to continue them in suspected pneumonia. BNP reflects myocardial wall stretch and volume overload, so elevated levels support heart failure as a cause of dyspnea and help guide diuretic therapy, escalation of HF-directed treatments, and prognosis. Used together, they address both potential etiologies: procalcitonin for pneumonia management and BNP for heart failure management.

In contrast, CRP and ESR are nonspecific markers of inflammation and don’t provide actionable guidance for antibiotic use or HF management. D-dimer and fibrinogen relate more to thromboembolism risk, not to guiding pneumonia or HF treatment. Troponin I and CK-MB indicate myocardial injury but aren’t as useful for distinguishing infection from heart failure or for guiding pneumonia therapy.